Poor nutrition is a major global health problem, contributing to half of the nearly 10 million deaths that occur each year in children younger than 5 and much of the death disease and suffering impacting sub-Saharan Africa. A starchy root crop called cassava is the major source of calories for more than 250 million Africans in this region, but cassava has the lowest protein-to-energy ratio of any staple crop. Dr. Sayre is leading a multidisciplinary team of scientists, brought together as BioCassava Plus, that is working to create nutritious cassava for sub-Saharan Africa. Team members are screening additional transgenic plants and expect that complimentary genetic strategies currently underway will soon yield plants that achieve their targeted levels of iron, zinc, and protein.

To maintain stability and viability, most childhood vaccines must be kept cool – both heat and freezing can ruin them. That means many must be refrigerated at the correct temperature throughout transportation, storage, and delivery. This cold chain is difficult and costly to maintain, especially in developing countries. Dr. Gardner and his colleagues are adapting high-throughput formulation technology developed by TransForm Pharmaceuticals, Inc. that can quickly screen different formulations of vaccines to identify those that are most likely to be stable, safe, and effective. The team's initial work focuses on reducing refrigeration requirements for the existing live attenuated vaccine for measles, a freeze-dried vaccine that must be stored at between 2° and 8° Celsius and is very sensitive to heat and light once it is reconstituted.

David Olson from the University of Alberta in Canada will work to better understand how infections can cause preterm birth. Using animal models and later in studies of women in low-income countries, he and his team will investigate multiple mediators of inflammation in the uterus early in pregnancy, as well as test new diagnostics and therapeutics that can identify women at risk, modulate the inflammatory response, and prolong pregnancy. Funding partners: Global Alliance to Prevent Prematurity and Stillbirth (GAPPS) and Bill & Melinda Gates Foundation.

In the developing world, many people with health problems never receive an accurate diagnosis or appropriate treatment because clinicians lack tools to detect and diagnose diseases and conditions quickly, accurately, and inexpensively. Sophisticated medical tests that could help improve care are not only often unaffordable, they require extensive laboratory facilities and deliver results days later – a hardship for people who may live many miles from the nearest health clinic. Dr. Kelso's team is developing rapid, affordable, point­-of-­care systems for both immunological and molecular tests. The project's objective is to design low­-cost delivery platforms that can perform assays in resource­-poor settings.